Clinical trials: Depressive State
Treatment Resistant Depression
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the…
- Trial name
- NCT04519957
- Where
- 8 sites in United States, Czechia and 3 more
- Volunteers
- 66 people
- Sponsor
- COMPASS Pathways
Treatment Resistant Depression
Virtual Neuro-Navigation System for Personalized Community Based TMS
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
- Trial name
- NCT04956081
- Testing
- Neuro-navigated Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Soterix Medical
Major Depression
Low Dose St John's Wort for Depression
This observational study observes the routine use of low-dose St John's Wort herbal mother tincture in patients with major depression.
- Trial name
- NCT05477472
- Testing
- St John's Wort
- Where
- Switzerland
- Volunteers
- 55 people
- Sponsor
- Ceres Heilmittel AG
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
- Trial name
- NCT00358631
- Testing
- SSR149415
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Sanofi
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depression
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the…
- Trial name
- NCT02237937
- Testing
- Paroxetine, Sertraline, Citalopram
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
Depression
Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment
This study evaluates the use of brain activity monitoring for early identification of pharmaceutical treatment efficacy and development of depression deterioration events.
- Trial name
- NCT02523105
- Testing
- EEG monitoring
- Where
- 2 sites in Israel
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brainmarc Ltd.
Depression, Depression Moderate
Kintsugi Voice Device Pilot Study
A prospective, single arm, non-randomized, pilot clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made…
- Conditions
- Depression, Depression Moderate, Depression Severe, Depression Mild
- Trial name
- NCT06374056
- Testing
- Kintsugi Voice Device
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depression, Dysthymia
Online System for Identifying and Addressing Teen Depression in Primary Care
A novel web-based module (Teen Depression Module or TDM)has been created for assisting primary care providers (PCPs) in screening for and addressing and referring teens with depression.
- Conditions
- Major Depression, Dysthymia, Depressive Symptoms
- Trial name
- Depression (NCT04489485)
- Testing
- Teen Depression Module used for care
- Where
- United States
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Total Child Health, Inc.
Bipolar I Disorder, Bipolar II Disorder
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- NCT06696755
- Testing
- Icalcaprant
- Where
- 33 sites in United States
- Volunteers
- 195 people
- Sponsor
- AbbVie
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Chronic Pain, Anxiety
Nu-V3 Non-Invasive Nerve Stimulation Device Trial for Chronic Pain, Anxiety, Depression, Sleeplessness
The Nu-V3 Clinical Study is a prospective, single-arm, open-label, multi-center study using the Nu-V3 cranial nerve stimulation treatment device in patients with chronic pain, anxiety, depression, and/or sleeplessness.
- Conditions
- Chronic Pain, Anxiety, Depression, Sleeplessness
- Trial name
- Nu-V3 (NCT05335980)
- Testing
- Nu-V3
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nu-Life Solutions
Major Depressive Disorder
Assessing Symptomatic Clinical Episodes in Depression
Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.
- Trial name
- ASCEND (NCT03595579)
- Testing
- AXS-05, Bupropion
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Axsome Therapeutics, Inc.
Menopause
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in…
- Trial name
- MPS (NCT04001088)
- Testing
- Probiotic
- Where
- 5 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Perimenopause, Perimenopausal Depression
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms…
- Conditions
- Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
- Trial name
- NCT07022925
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- IdentifyHer Limited
Depression Disorders, Anxiety Disorders
Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety
This study evaluates the reliability and responsiveness of the AI-COA®, a digital tool designed to assess the severity of depression and anxiety.
- Trial name
- SEQUOIA-2 (NCT07279025)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Deliberate Solutions Inc.
Depression - Major Depressive Disorder, Anxiety
Validation of Accexible Screening and Self-Administered Activities for Emotional Well-Being in a University Hospital (UaDEC)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07578155
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Accexible
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
- Trial name
- NCT07161700
- Testing
- SPT-300
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Major Depressive Disorder (MDD)
A Phase II Study to Evaluate NH102 for Depression
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine .
- Trial name
- NH102-21 (NCT06842992)
- Testing
- NH102, Duloxetine Hydrochloride Enteric-coated Capsule
- Where
- 24 sites in China
- Volunteers
- 243 people
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.